INTRODUCTION
Erythema nodosum is a common form of panniculitis. Typically, they are tender erythematous nodules and raised plaques on the anterior aspects of legs. The etiologic factors and pathogenesis are not yet fully understood. Erythema nodosum is associated with a variety of clinical conditions, including infection, medication, autoimmune disorders, pregnancy, and malignancy. It is well-known that the etiology of erythema nodosum is associated with female sex hormones -estrogen and progesterone 1 . As pregnancies conceived through assisted reproductive therapy increase, we predict that the incidence of erythema nodosum in women who underwent assisted reproductive therapy will increase. We herein report a case of erythema nodosum caused by progesterone injection for endometrial preparation.
CASE REPORT
A 33 year-old Korean woman presented with a 1-week history of painful erythematous plaques on both knees. Physical examination showed symmetric, tender, erythematous plaques on the anterior aspects of both knees (Fig.  1A) . Pain was aggravated by exercise, particularly during walking. Although the lesions were warm, she had no fever. She was systemically well in the seventh week of her first pregnancy. She had never used oral contraceptives. She had become pregnant after undergoing assisted reproductive therapy. Intramuscular injection of progesterone (50 mg) had been administered daily for to enable endometrial preparation for 4 weeks. There was no history of upper respiratory infection before her presentation. She had only received hormonal assisted reproductive therapy.
We noted thickened septa with infiltrated inflammatory cells without evidence of vasculitis ( Fig. 2A ). There were also inflammatory cells in the periseptal areas of the fat lobules (Fig. 2B ). We diagnosed our patient with erythema nodosum following histopathological evaluation. Intramuscular progesterone therapy was ceased and instead she began to receive vaginal topical progesterone (Crinone gel Ⓡ ). Two days after discontinuing intramuscular progesterone injection, clinical improvement was observed (Fig. 1B) . The lesions started to resolve, and the color of lesions became darker and more brown. We added acetaminophen treatment. Progesterone continued to be administered for endometrial preparation in the following manner: 4 weeks intramuscularly and 3 weeks topically to the vagina. At the time of preparing this publication, there has been no evidence of recurrence.
DISCUSSION
Erythema nodosum is the most frequent clinicopathologic variant of septal panniculitis 2 . Since first described in 1798, various etiologic factors have been identified: streptococcal infections, sarcoidosis, autoimmune disorders, inflammatory bowel diseases, drugs such as oral contraceptives 3 and malignancy 1, 4 . Nevertheless, the etiology cannot be confirmed in 37 to 60% of cases of erythema nodosum 4 .
In a prospective study of 132 patients diagnosed with erythema nodosum, hormonal factors during pregnancy and oral contraceptives were the causes of 10% of cases 1 .
This is not the only evidence to suggest that female sex hormone is related to erythema nodosum. After puberty, erythema nodosum follows a female predominance, but before puberty, the sex incidence is approximately equal 4 .
In addition, there are cases of erythema nodosum in the course of hormone replacement therapy in postmenopausal women 5 and after aromatase inhibitor administration in breast cancer patients 6 .
If then, which factor of female sex hormones could cause erythema nodosum? The concentrations of these hormones are thought to be critical in the development of erythema nodosum 7 . There was no report of erythema nodosum associated with high-dose estrogen salvage therapy for metastatic breast cancer, while low-dose hormone replacement therapy in postmenopausal women can cause erythema nodosum 5 . Furthermore, erythema nodosum commonly occurs during the first trimester of gestation, but not in the third trimester. In addition, erythema nodosum has been observed in breast cancer patients treated with aromatase inhibitors, which suppresses plasma estrogen levels 6 . This presented case demonstrates that sole progesterone therapy can cause erythema nodosum. The fact that skin lesions began to resolve after commencing topical progesterone, which led to reduction in serum progesterone concentration although not measured clinically, is consistent with this hypothesis. Therefore, we suggest that the concentration of progesterone or the ratio between estrogen and progesterone is more important in the pathogenesis of erythema nodosum than the concentration of estrogen alone. Keratinocytes from overlying epidermis in erythema nodosum lesions were negative for both estrogen and progesterone receptors, like other normal human skin 8 . However, the expression levels of progesterone receptor in other tissues of erythema nodosum patients remain unknown. It has not been confirmed whether the effect of progesterone in erythema nodosum is direct or indirect. Further studies will be needed to address these questions. Progesterone is critical in the process of endometrial preparation to maintain pregnancy. Either insufficient progesterone concentration or insufficient progesterone response may lead to pregnancy loss. A recent study shows that normal endometrium is highly sensitive to very low levels of progesterone 9 . Furthermore, no statistically significant benefit has been observed in intramuscular progesterone administration over topical administration to vagina 10 . Since the quantity of hormones in oral contraceptives has been decreased after the 1980s, erythema nodosum caused by oral contraceptive is now rare. Nowadays, the use of assisted reproductive therapy has become popular. The advancement of related technology will hopefully lead to reduced dosage of progesterone required for endometrial preparation, and consequently lessen the incidence of erythema nodosum, as was the case with oral contraceptives.
To our knowledge, assisted reproductive therapy-induced erythema nodosum has never been reported. However it should be considered as a possible adverse event in assisted reproductive therapy.
